A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
- 27 October 2009
- Vol. 27 (52) , 7292-7298
- https://doi.org/10.1016/j.vaccine.2009.10.087
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in MaliVaccine, 2009
- A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervalsVaccine, 2009
- A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in MaliVaccine, 2009
- Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian childrenMalaria Journal, 2008
- Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: Implications for vaccine designProceedings of the National Academy of Sciences, 2008
- Breadth and Magnitude of Antibody Responses to MultiplePlasmodium falciparumMerozoite Antigens Are Associated with Protection from Clinical MalariaInfection and Immunity, 2008
- Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccinesVaccine, 2008
- Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult MaliansPLOS ONE, 2007
- Structural basis of antigenic escape of a malaria vaccine candidateProceedings of the National Academy of Sciences, 2007
- Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9Proceedings of the National Academy of Sciences, 2007